Galera Therapeutics - News Releases

Oct 12, 2021	Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer	View HTML PDF Version
Sep 14, 2021	Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer	View HTML PDF Version
Sep 08, 2021	Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters	View HTML PDF Version
Sep 07, 2021	Galera to Present at Three Upcoming Investor Conferences in September	View HTML PDF Version
Aug 10, 2021	Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments	View HTML PDF Version
Jun 28, 2021	Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis	View HTML PDF Version
May 26, 2021	Galera to Present at the Jefferies Virtual Healthcare Conference	View HTML PDF Version
May 17, 2021	Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer	View HTML PDF Version
May 12, 2021	Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors	View HTML PDF Version
May 11, 2021	Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments	View HTML PDF Version